BACKGROUND: Posterior fossa ependymoma (PFE) comprises 2 groups, PF group A (PFA) and PF group B (PFB), with stark differences in outcome. However, to the authors' knowledge, the long-term outcomes of PFA ependymoma have not been described fully. The objective of the current study was to identify predictors of survival and neurocognitive outcome in a large consecutive cohort of subgrouped patients with PFE over 30 years. METHODS: Demographic, survival, and neurocognitive data were collected from consecutive patients diagnosed with PFE from 1985 through 2014 at the Hospital for Sick Children in Toronto, Ontario, Canada. Subgroup was assigned using genome-wide methylation array and/or immunoreactivity to histone H3 K27 trimethylation (H3K27me3). RESULTS: A total of 72 PFE cases were identified, 89% of which were PFA. There were no disease recurrences noted among patients with PFB. The 10-year progression-free survival rate for all patients with PFA was poor at 37.1% (95% confidence interval, 25.9%-53.1%). Analysis of consecutive 10-year epochs revealed significant improvements in progression-free survival and/or overall survival over time. This pertains to the increase in the rate of gross (macroscopic) total resection from 35% to 77% and the use of upfront radiotherapy increasing from 65% to 96% over the observed period and confirmed in a multivariable model. Using a mixed linear model, analysis of longitudinal neuropsychological outcomes restricted to patients with PFA who were treated with focal irradiation demonstrated significant continuous declines in the full-scale intelligence quotient over time with upfront conformal radiotherapy, even when correcting for hydrocephalus, number of surgeries, and age at diagnosis (-1.33 ± 0.42 points/year; P = .0042). CONCLUSIONS: Data from a molecularly informed large cohort of patients with PFE clearly indicate improved survival over time, related to more aggressive surgery and upfront radiotherapy. However, to the best of the authors' knowledge, the current study is the first, in a subgrouped cohort, to demonstrate that this approach results in reduced neurocognitive outcomes over time.

Department of Paediatric Haematology and Oncology 2nd Medical School Charles University and University Hospital Motol Prague Czech Republic

Department of Paediatric Hematology and Oncology Child Jesus Hospital Madrid Spain

Department of Paediatric Laboratory Medicine Hospital for Sick Children Toronto Ontario Canada

Department of Pediatric Oncology Birmingham Children's Hospital NHS Foundation Trust Birmingham United Kingdom

Department of Psychology Hospital for Sick Children Toronto Ontario Canada

Department of Psychology University of Toronto Toronto Ontario Canada

Department of Radiation Oncology Princess Margaret Cancer Center Toronto Ontario Canada

Division of Endocrinology Hospital for Sick Children Toronto Ontario Canada

Division of Haematology Oncology Hospital for Sick Children Toronto Ontario Canada

Division of Neurosurgery Hospital for Sick Children Toronto Ontario Canada

Programme in Developmental and Stem Cell Biology Hospital for Sick Children Toronto Ontario Canada

Programme in Neuroscience and Mental Health Hospital for Sick Children Toronto Ontario Canada

Zobrazit více v PubMed

Khatua S, Ramaswamy V, Bouffet E. Current therapy and the evolving molecular landscape of paediatric ependymoma. Eur J Cancer 2017;70: 34–41. PubMed

Ramaswamy V, Hielscher T, Mack SC, et al. Therapeutic Impact of Cytoreductive Surgery and Irradiation of Posterior Fossa Ependymoma in the Molecular Era: A Retrospective Multicohort Analysis. J Clin Oncol 2016. PubMed PMC

Merchant TE, Li C, Xiong X, Kun LE, Boop FA, Sanford RA. Conformal radiotherapy after surgery for paediatric ependymoma: a prospective study. Lancet Oncology 2009;10: 258–266. PubMed PMC

Cavalli FMG, Hubner JM, Sharma T, et al. Heterogeneity within the PF-EPN-B ependymoma subgroup. Acta Neuropathol 2018;136: 227–237. PubMed PMC

Pajtler KW, Mack SC, Ramaswamy V, et al. The current consensus on the clinical management of intracranial ependymoma and its distinct molecular variants. Acta Neuropathol 2017;133: 5–12. PubMed PMC

Pajtler KW, Witt H, Sill M, et al. Molecular Classification of Ependymal Tumors across All CNS Compartments, Histopathological Grades, and Age Groups. Cancer Cell 2015;27: 728–743. PubMed PMC

Witt H, Mack SC, Ryzhova M, et al. Delineation of two clinically and molecularly distinct subgroups of posterior fossa ependymoma. Cancer Cell 2011;20: 143–157. PubMed PMC

Mack SC, Witt H, Piro RM, et al. Epigenomic alterations define lethal CIMP-positive ependymomas of infancy. Nature 2014;506: 445–450. PubMed PMC

Zapotocky M, Ramaswamy V, Lassaletta A, Bouffet E. Adolescents and young adults with brain tumors in the context of molecular advances in neuro-oncology. Pediatr Blood Cancer 2018;65. PubMed

Grundy RG, Wilne SH, Robinson KJ, et al. Primary postoperative chemotherapy without radiotherapy for treatment of brain tumours other than ependymoma in children under 3 years: Results of the first UKCCSG/SIOP CNS 9204 trial. European Journal of Cancer 2010;46: 120–133. PubMed

Grundy RG, Wilne SA, Weston CL, et al. Primary postoperative chemotherapy without radiotherapy for intracranial ependymoma in children: the UKCCSG/SIOP prospective study. Lancet Oncol 2007;8: 696–705. PubMed

Mulhern RK, Merchant TE, Gajjar A, Reddick WE, Kun LE. Late neurocognitive sequelae in survivors of brain tumours in childhood. Lancet Oncol 2004;5: 399–408. PubMed

Merchant TE, Mulhern RK, Krasin MJ, et al. Preliminary results from a phase II trial of conformal radiation therapy and evaluation of radiation-related CNS effects for pediatric patients with localized ependymoma. J Clin Oncol 2004;22: 3156–3162. PubMed

Strother DR, Lafay-Cousin L, Boyett JM, et al. Benefit from prolonged dose-intensive chemotherapy for infants with malignant brain tumors is restricted to patients with ependymoma: a report of the Pediatric Oncology Group randomized controlled trial 9233/34. Neuro Oncol 2014;16: 457–465. PubMed PMC

Duffner PK, Horowitz ME, Krischer JP, et al. Postoperative chemotherapy and delayed radiation in children less than three years of age with malignant brain tumors. N Engl J Med 1993;328: 1725–1731. PubMed

Aarsen FK, Paquier PF, Arts WF, et al. Cognitive Deficits and Predictors 3 Years After Diagnosis of a Pilocytic Astrocytoma in Childhood. Journal of Clinical Oncology 2009;27: 3526–3532. PubMed

Venneti S, Santi M, Felicella MM, et al. A sensitive and specific histopathologic prognostic marker for H3F3A K27M mutant pediatric glioblastomas. Acta Neuropathol 2014;128: 743–753. PubMed PMC

Moxon-Emre I, Bouffet E, Taylor MD, et al. Impact of Craniospinal Dose, Boost Volume, and Neurologic Complications on Intellectual Outcome in Patients With Medulloblastoma. J Clin Oncol 2014. PubMed

Moxon-Emre I, Taylor MD, Bouffet E, et al. Intellectual Outcome in Molecular Subgroups of Medulloblastoma. J Clin Oncol 2016;34: 4161–4170. PubMed

Lassaletta A, Bouffet E, Mabbott D, Kulkarni AV. Functional and neuropsychological late outcomes in posterior fossa tumors in children. Childs Nerv Syst 2015;31: 1877–1890. PubMed

Pajtler KW, Wen J, Sill M, et al. Molecular heterogeneity and CXorf67 alterations in posterior fossa group A (PFA) ependymomas. Acta Neuropathol 2018;136: 211–226. PubMed PMC

Merchant TE, Sharma S, Xiong X, Wu S, Conklin H. Effect of cerebellum radiation dosimetry on cognitive outcomes in children with infratentorial ependymoma. Int J Radiat Oncol Biol Phys 2014;90: 547–553. PubMed PMC

Willard VW, Conklin HM, Boop FA, Wu S, Merchant TE. Emotional and behavioral functioning after conformal radiation therapy for pediatric ependymoma. Int J Radiat Oncol Biol Phys 2014;88: 814–821. PubMed PMC

Netson KL, Conklin HM, Wu S, Xiong X, Merchant TE. A 5-year investigation of children’s adaptive functioning following conformal radiation therapy for localized ependymoma. Int J Radiat Oncol Biol Phys 2012;84: 217–223 e211. PubMed PMC

Conklin HM, Li C, Xiong X, Ogg RJ, Merchant TE. Predicting change in academic abilities after conformal radiation therapy for localized ependymoma. J Clin Oncol 2008;26: 3965–3970. PubMed PMC

Merchant TE, Rose SR, Bosley C, Wu S, Xiong X, Lustig RH. Growth hormone secretion after conformal radiation therapy in pediatric patients with localized brain tumors. J Clin Oncol 2011;29: 4776–4780. PubMed PMC

Macdonald SM, Sethi R, Lavally B, et al. Proton radiotherapy for pediatric central nervous system ependymoma: clinical outcomes for 70 patients. Neuro Oncol 2013;15: 1552–1559. PubMed PMC

Conklin HM, Ashford JM, Clark KN, et al. Long-Term Efficacy of Computerized Cognitive Training Among Survivors of Childhood Cancer: A Single-Blind Randomized Controlled Trial. J Pediatr Psychol 2016. PubMed PMC

Conklin HM, Ogg RJ, Ashford JM, et al. Computerized Cognitive Training for Amelioration of Cognitive Late Effects Among Childhood Cancer Survivors: A Randomized Controlled Trial. J Clin Oncol 2015;33: 3894–3902. PubMed PMC

Piscione PJ, Bouffet E, Timmons B, et al. Exercise training improves physical function and fitness in long-term paediatric brain tumour survivors treated with cranial irradiation. Eur J Cancer 2017;80: 63–72. PubMed

Ameis SH, Daskalakis ZJ, Blumberger DM, et al. Repetitive Transcranial Magnetic Stimulation for the Treatment of Executive Function Deficits in Autism Spectrum Disorder: Clinical Trial Approach. J Child Adolesc Psychopharmacol 2017;27: 413–421. PubMed PMC

Riggs L, Piscione J, Laughlin S, et al. Exercise training for neural recovery in a restricted sample of pediatric brain tumor survivors: a controlled clinical trial with crossover of training versus no training. Neuro Oncol 2017;19: 440–450. PubMed PMC

Wang J, Gallagher D, DeVito LM, et al. Metformin activates an atypical PKC-CBP pathway to promote neurogenesis and enhance spatial memory formation. Cell Stem Cell 2012;11: 23–35. PubMed

Survival and functional outcomes in paediatric thalamic and thalamopeduncular low grade gliomas